Cholinergic modulation of hippocampal activity during episodic memory encoding in postmenopausal women: A pilot study

Menopause

Volumn 17, Issue 4, 2010, Pages 852-859

  Dumas, Julie A ^a   McDonald, Brenna C ^b   Saykin, Andrew J ^b   McAllister, Thomas W ^c   Hynes, Mary L ^c   West, John D ^b   Newhouse, Paul A ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Cholinergic system; Episodic memory; Functional magnetic resonance imaging; Postmenopausal women

Indexed keywords

CHOLINERGIC RECEPTOR; MECAMYLAMINE; PLACEBO; SCOPOLAMINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; SCOPOLAMINE BROMIDE;

ADULT; AGED; ARTICLE; BEHAVIOR; CHOLINERGIC ACTIVITY; CONTROLLED STUDY; EPISODIC MEMORY; FEMALE; FRONTAL LOBE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIPPOCAMPUS; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; OCCIPITAL LOBE; PILOT STUDY; POSTMENOPAUSE; PROVOCATION TEST; RECOGNITION; TASK PERFORMANCE; VERBAL MEMORY; VISUAL MEMORY; VITAL SIGN; BRAIN; BRAIN MAPPING; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOLOGY;

AGED; BRAIN; BRAIN MAPPING; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MECAMYLAMINE; MEMORY; MIDDLE AGED; MUSCARINIC ANTAGONISTS; NEUROPSYCHOLOGICAL TESTS; NICOTINIC ANTAGONISTS; PILOT PROJECTS; POSTMENOPAUSE; SCOPOLAMINE HYDROBROMIDE;

EID: 77954913419     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181e04db9     Document Type: Article

References (47)

1. Weber M, Mapstone M. Memory complaints and memory performance in the menopausal transition. Menopause 2009;16:1-7.
2. Light LL, Prull MW, La Voie DJ, Healy MR. Dual-process theories of memory in old age. In: Perfect TJ, Maylor EA, eds. Models of Cognitive Aging. Debates in Psychology. New York, NY: Oxford University Press, 2000:238-300.
3. Halbreich U, Lumley LA, Palter S, Manning C, Gengo F, Joe S-h. Possible acceleration of age effects on cognition following menopause. J Psychiatr Res 1995;29:153-163.
4. Gibbs RB. Estrogen therapy and cognition: a review of the cholinergic hypothesis. Endocr Rev 2010;31:224-253.
5. Dumas JA, Hancur-Bucci C, Naylor M, Sites C, Newhouse PA. Estrogen treatment effects on anticholinergic-induced cognitive dysfunction in normal post-menopausal women. Neuropsychopharmacology 2006;31: 2065-2078.
6. Dumas JA, Hancur-Bucci C, Naylor M, Sites C, Newhouse P. Estrogen interacts with the cholinergic system to affect the verbal memory in postmenopausal women: evidence for the critical period hypothesis. Horm Behav 2008;53:159-169.
7. Dumas JA, Saykin AJ, McAllister TW, McDonald BC, Hynes ML, Newhouse PA. Nicotinic versus muscarinic blockade alters verbal working memory-related brain activity in older women. Am J Geriatr Psychiatry 2008;16:272-282.
8. Kopelman MD. The cholinergic neurotransmitter system in human memory and dementia: a review. Q J Exp Psychol 1986;38:535-573.
9. Kopelman MD, Corn TH. Cholinergic Fblockade' as a model for cho-linergic depletion. A comparison of the memory deficits with those of Alzheimer's-type dementia and the alcoholic Korsakoff syndrome. Brain 1988;111:1079-1110.
10. Sunderland T, Tariot P, Murphy DL, Weingartner H, Mueller EA, Cohen RM. Scopolamine challenges in Alzheimer's disease. Psychophar-macology 1985;87:247-249.
11. Sunderland T, Tariot P, Weingartner H, et al. Pharmacologic modeling of Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1986;10:599-610.
12. Curran HV, Pooviboonsuk P, Dalton JA, Lader MH. Differentiating the effects of centrally acting drugs on arousal and memory: an event-related potential study of scopolamine, lorazepam, and diphenhydramine. Psychopharmacology 1998;135:27-36.
13. Kamboj SK, Curran HV. Neutral and emotional episodic memory: global impairment after lorazepam or scopolamine. Psychopharmacology 2006; 188:482-488.
14. Kamboj SK, Curran HV. Scopolamine induces impairments in the recog-nition of human facial expressions of anger and disgust. Psychopharma-cology 2006;185:529-535.
15. Erskine FF, Ellis JR, Ellis KA, et al. Evidence for synergistic mod-ulation of early information processing by nicotinic and muscar-inic receptors in humans. Hum Psychopharmacol Clin Exp 2004;19: 503-509.
16. Green A, Ellis KA, Ellis J, et al. Muscarinic and nicotinic receptor modulation of object and spatial n-back working memory in humans. Pharmacol Biochem Behav 2005;81:575-584.
17. Gron G, Brandenburg I, Wunderlich AP, Reipe MW. Inhibition of hip-pocampal function in mild cognitive impairment: targeting the cholinergic hypothesis. Neurobiol Aging 2006;27:78-87.
18. Thiel CM. Cholinergic modulation of learning and memory in the human brain as detected with functional neuroimaging. Neurobiol Learn Mem 2003;80:234-244.
19. Schon K, Atri A, Hasselmo ME, Tricarico MD, LoPresti ML, Stern CE. Scopolamine reduces persistent activity related to long-term encoding in the parahippocampal gyrus during delayed matching in humans. J Neurosci 2005;25:9112-9123.
20. Sperling R, Greve D, Dale A, et al. Functional MRI detection of phar-macologically induced memory impairment. Proc Natl Acad Sci USA 2002;99:455-460.
21. Craig MC, Fletcher PC, Daly EM, et al. The interactive effect of the cholinergic system and acute ovarian suppression on the brain: an fMRI study. Horm Behav 2009;55:41-49.
22. Craig MC, Brammer M, Maki PM, et al. The interactive effect of acute ovarian suppression and the cholinergic system on visuospatial working memory in young women [e-pub]. Psychoneuroendocrinology 2010.
23. Bartholomeusz CF, Wesnes KA, Kulkarni J, Vietta L, Croft RJ, Nathan PJ. Estradiol treatment and its interaction with the cholinergic system: effects on cognitive function in healthy young women. Horm Behav 2008;54:684-693.
24. Johnson JD, Muftuler LT, Rugg MD. Multiple repetitions reveal func-tionally and anatomically distinct patterns of hippocampal activity during continuous recognition. Hippocampus 2008;18:975-980.
25. Newhouse PA, Potter A, Kelton M, Corwin J. Nicotinic treatment of Alzheimer's disease. Biol Psychiatry 2001;49:269-278.
26. Shaywitz SE, Shaywitz BA, Pugh KR, et al. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA 1999;281:1197-1202.
27. Folstein MF, Folstein SE, McHugh PR. BMini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
28. Reisberg B, Ferris SH, de Leon MJ, Crook T. Global Deterioration Scale (GDS). Psychopharmacol Bull 1988;24:661-663.
29. Jurica PJ, Leitten CL, Mattis S. Dementia Rating Scale-2. Lutz, FL: Psychological Assessment Resources Inc., 2001.
30. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders-Patient Edition (SCID-I/P, 2/2001 ed). Washington, DC: American Psychiatric Press Inc., 2001.
31. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:53-63.
32. McNair DM, Lorr M, Droppleman LF. Profile of Mood States. San Diego, CA: Educational and Industrial Testing Service, 1971.
33. Hoddes ElZ, Zarcone V, Smythe H, Phillips R, Dement W. Quantifica-tion of sleepiness: a new approach. Psychophysiology 1973;10:431-436.
34. Newhouse PA, Potter A, Corwin J, Lenox R. Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. Neuro-psychopharmacology 1994;10:93-107.
35. Overall J, Gorham D. The Brief Psychiatric Rating Scale. Psychol Rep 1993;10:799-812.
36. Kucera H, Francis WN. Computational Analysis of Present-Day American English. Providence, RI: Brown University Press, 1967.
37. Toglia MP, Battig WF. Handbook of Semantic Word Norms. Hillsdale, NJ: Erlbaum, 1978.
38. Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 1995;2:189-210.
39. Holmes A, Friston K. Generalizability, random effects, and population inferences. Neuroimage 1998;7:S754.
40. Lancaster JL, Woldorff MG, Parsons LM, et al. Automated Talairach atlas labels for functional brain mapping. Hum Brain Mapp 2000;10:120-131.
41. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH. An automated method for neuroanatomic and cytoarchitectonic atlas-based interroga-tion of fMRI data sets. Neuroimage 2003;19:1233-1239.
42. Snodgrass J, Corwin J. Pragmatics of measuring recognition memory: applications to dementia and amnesia. J Exp Psychol 1988;117:34-50.
43. Sunderland T, Tariot PN, Newhouse PA. Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuro-psychiatric populations. Brain Res Rev 1988;13:371-389.
44. Giessing C, Thiel CM, Rosler F, Fink GR. The modulatory effects of nicotine on parietal cortex activity in a cued target detection task depend on cue reliability. Neuroscience 2006;137:853-864.
45. Bentley P, Husain MK, Dolan RJ. Effects of cholinergic enhancement on visual stimulation, spatial attention, and spatial working memory. Neuron 2004;41:969-982.
46. Davis SW, Dennis NA, Daselaar SM, Fleck MS, Cabeza R. Que PASA? The posterior anterior shift in aging. Cereb Cortex 2008;18:1201-1209.
47. Warburton DM, Rusted JM. Cholinergic control of cognitive resources. Neuropsychobiology 1993;28:43-46.